TD Cowen raises Caris Life Sciences stock price target on pipeline
TD Cowen raised its price target for Caris Life Sciences (CAI) to $38 from $36, maintaining a Buy rating. The company reported Q3 sales beating expectations by 9%, with revenue up 85% year-over-year and a 70% gross margin. Despite this, shares fell 15% post-market due to an earnings miss. The stock has gained 65% since pre-Q2 levels, but InvestingPro suggests it may be overvalued.
How this was made
The 30-second read
Why it matters
The earnings miss triggered a 15% post‑close decline despite a higher price target, indicating short‑term weakness.
Market read
Earnings release with mixed signals; price target raise may not offset profit miss, leading to near‑term downside risk.
What to watch
Clinical volume growth and strong gross margins could support a turnaround if cost discipline improves.
Background
Caris Life Sciences reported Q3 results with 85% YoY revenue growth, a 9% sales beat, but earnings of $0.05 vs $0.16 expected.
Ticker impact
TD Cowen raised its price target on Caris Life Sciences (CAI) to $38 after the company reported Q3 sales beat but missed profit expectations, causing a 15% post‑close decline.
downward pressure as investors price in the earnings miss and profit shortfall
The stock fell 15% after hours; the profit miss outweighs the sales beat and target raise, likely prompting further short‑term selling.
Market effects
Highlights volatility in the biotech services sector where sales growth may not translate to earnings, prompting caution on peers.
U.S. biotech stocks may see modest pullback as investors reassess profit expectations.
Limited to biotech and healthcare investors; no broad market effect.
Counterpoint
The raised price target suggests upside potential if the company can convert sales growth into profitability.
Key entities
- companyCaris Life Sciences Inc.
U.S. biotech services firm (NASDAQ:CAI).
- analystTD Cowen
Equity research firm that raised CAI's price target.


